Evonik's biggest shareholder, the RAG foundation, has confirmed it still intends to reduce its 43% holding in the German specialty-chemicals company to 25.1%, even after BASF abandoned its takeover attempt. The announcement shifts the focus from a potential bid to the mechanics of a large, gradual share sale.
RAG told Reuters it wants to sell down its position gradually, and it criticized BASF for ending talks before the two companies' leadership had detailed discussions. BASF, for its part, said it walked away because Evonik would not engage, even after BASF signaled it could raise its offer. The breakdown of negotiations sent Evonik shares down 16% in a single day, the steepest drop on record, to around €18 — far below the €24 per share that BASF had most recently floated.
What happened between BASF and Evonik?
BASF, one of the world's largest chemical companies, had been circling Evonik for months. Reports of a potential takeover emerged earlier this year, and BASF reportedly made an €11.2 billion approach that Evonik rejected. The two sides never reached a formal agreement, and BASF eventually pulled out, citing Evonik's unwillingness to engage in meaningful talks.
For investors, the collapse of the takeover removes the "takeover premium" that had been baked into Evonik's share price. When a company is seen as a potential acquisition target, its stock often trades higher than its standalone value, because buyers are expected to pay a premium to gain control. With BASF out of the picture, that premium has evaporated, and the market is now pricing Evonik based on its fundamentals and the prospect of a large share sale.
What RAG's planned stake cut means
RAG's decision to reduce its stake from 43% to 25.1% is significant for several reasons. First, it creates a "share overhang" — a situation where investors know that a large block of shares is likely to come to market, which can cap any rally in the stock. Until RAG provides a clear timetable and pricing for its sell-down, buyers may be reluctant to push the share price higher, fearing they could be undercut by a discounted block trade.
Second, the way RAG sells its shares matters. Large holders often dispose of stakes through block trades or placements, sometimes at a discount to the current market price to attract buyers. This can put immediate downward pressure on the stock, especially if the market perceives the discount as too steep.
Third, RAG's intention to keep 25.1% is not arbitrary. In many European companies, a 25% stake is enough to block certain major shareholder votes, such as changes to the company's articles of association or other supermajority decisions. This means RAG could retain significant influence over Evonik's governance even after reducing its holding, which may keep some control questions unresolved.
What it means for investors
For everyday investors, the key takeaway is that Evonik's stock is now more likely to be driven by supply dynamics than by takeover speculation. With BASF no longer in the frame, the near-term valuation will depend on who absorbs RAG's shares and at what discount. Until that path is clearer, the stock could trade with a structural markdown and experience larger day-to-day swings than it would if the shareholder register were stable.
Investors should also watch for any announcements from RAG about the mechanics of the sale. A well-structured placement, done gradually and at a reasonable discount, could minimize the impact on the share price. Conversely, a rushed or large block sale could exacerbate the decline.
For those holding Evonik shares, the situation underscores the importance of understanding the shareholder structure and the potential for overhangs. It also highlights the risks of buying a stock purely on takeover hopes — when the bid disappears, so does the premium.
As the story develops, the market will be looking for clarity on RAG's timeline and pricing. Until then, Evonik's shares are likely to remain under pressure, with the focus squarely on how a big seller exits gracefully.


